CMMB
Closed
Chemomab Therapeutics Ltd Drc
1.16
0.00 (0.00%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 1.16
Day's Range: 1.15 - 1.22
Send
sign up or login to leave a comment!
When Written:
1.59
Chemomab Therapeutics Ltd is a clinical-stage biotech company that develops innovative therapeutics for the treatment of fibrosis-related diseases, cancer, and inflammation. The company's lead drug candidate is CM-101, a monoclonal antibody that targets the CCL24 chemokine, which is involved in the development of fibrosis.
The company was founded in 2016 and is based in Israel. It went public on the NASDAQ stock exchange in February 2021, raising $60 million in its initial public offering.
Chemomab Therapeutics Ltd has partnerships with several pharmaceutical companies, including Eli Lilly and Company, which is collaborating with the company to develop CM-101 for the treatment of fibrosis-related diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The company was founded in 2016 and is based in Israel. It went public on the NASDAQ stock exchange in February 2021, raising $60 million in its initial public offering.
Chemomab Therapeutics Ltd has partnerships with several pharmaceutical companies, including Eli Lilly and Company, which is collaborating with the company to develop CM-101 for the treatment of fibrosis-related diseases.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








